A prognostic significance of axillary lymph nodes of cancer stem cells CD44, CD24, ALDH 1 based on pathological responses in triple negative breast cancer: A study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      TNBC (Triple-Negative Breast Cancer) is a diverse clinical and pathological entity around 15/20th of all BC (Breast Cancer) cases. This type of breast cancer has a high peril of subsequent and a terrible prognostic. Chemotherapy is a more effective technique for treating TNBC since it lacks the ER (Oestrogen Receptor), PR (Progesterone Receptor), and HER2 (Human Epidermal Growth Factor Receptor 2). CSC (The Cancer Stem Cell) hypothesis has significant diagnostic insinuation for cancer treatments owing to potential task of CSC in chemo-resistance. The most important prognostic variables in BC are the axillary lymph node condition, and that is a core part of the staging system. The CSC markers in BC are CD44, CD24, and ALDH 1, played a predictive role in TNBCs. Most of these indicators are in primary tumours, it lead to the capacity to identify individuals at increased risk of lymph node metastasis at the period of diagnosis, enabling earlier intervention and more appropriate adjuvant therapies. Unlike, chemotherapy, radiation, and other medications, this combination of indicators might be used to assess tumour development and predicting prognosis. The objective of this study is to investigate if the CSC markers CD44, CD24, and ALDH 1 in the axillary lymph nodes had any predictive significance in TNBC based on pathological responses. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of AIP Conference Proceedings is the property of American Institute of Physics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)